2.12  1.05 (98.13%)		03-13 16:00
Open: 1.805 High: 2.73 Volume: 238,988,638		Pre. Close: 1.07 Low: 1.78 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	3.18	1-year :	3.72
Resists	First :	2.73	Second :	3.18
Pivot price	1.12
Supports	First :	1.48	Second :	0.72
MAs	MA(5) :	1.31	MA(20) :	1.12
	MA(100) :	1.47	MA(250) :	5.98
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	48.8	D(3) :	46.8
RSI	RSI(14): 77.2
52-week	High :	46.52	Low :	0.69

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BIAF ] has closed above the upper band by 41.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 71% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	2.73 - 2.74	2.74 - 2.76
Low:	1.76 - 1.77	1.77 - 1.78
Close:	2.1 - 2.12	2.12 - 2.14

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Fri, 13 Mar 2026
Crude Oil Gains Over 1%; VEON Shares Spike Higher - Benzinga

Fri, 13 Mar 2026
bioAffinity Technologies Expands Lung Cancer Detection Initiatives - StocksToTrade

Fri, 13 Mar 2026
bioAffinity Technologies jumps 124% as it touts record 2025 CyPath Lung growth and outlines expansion plans - Quiver Quantitative

Fri, 13 Mar 2026
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga

Fri, 13 Mar 2026
BioAffinity Technologies Shakes Up Diagnostics Field with Innovative Clinical Initiatives - timothysykes.com

Fri, 13 Mar 2026
BIAF: CyPath® Lung test sales surged 99% in 2025, driving record revenue and future growth momentum - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	5 (M)
Shares Float	4 (M)
Held by Insiders	3.1 (%)
Held by Institutions	4.3 (%)
Shares Short	105 (K)
Shares Short P.Month	40 (K)

EPS	-13.83
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.56
Profit Margin	-217.5 %
Operating Margin	-158.6 %
Return on Assets (ttm)	-71.8 %
Return on Equity (ttm)	-245.2 %
Qtrly Rev. Growth	-38.5 %
Gross Profit (p.s.)	0.41
Sales Per Share	1.5
EBITDA (p.s.)	-2.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.16
PEG Ratio	0
Price to Book value	0.82
Price to Sales	1.4
Price to Cash Flow	-1.13

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.